{"entity":{"id":"nct05774951","kind":"trial","name":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","aka":["CAMBRIA-1"],"tldr":"A phase 3 trial of Camizestrant, Tamoxifen and Exemestane in advanced solid tumours, run by AstraZeneca, now recruiting.","summary":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy is a phase 3 interventional study registered as NCT05774951 by AstraZeneca, with 4300 participants planned, started 2023-03-31 and due to reach its primary completion in 2027-04-20. Interventions recorded: Camizestrant, Tamoxifen, Anastrozole, Letrozole and Exemestane.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05774951","url":"https://clinicaltrials.gov/study/NCT05774951"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":["camizestrant","tamoxifen","exemestane"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05774951","phase":"3","setting":"CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence","sponsor":"AstraZeneca","participation":[{"nct":"NCT05774951","source":"https://clinicaltrials.gov/study/NCT05774951","fetchedAt":"2026-10-07T16:53:55.392Z","studySha256":"2b57b347f1d2fe77e3ffa257e7c4bb285c3d2decbf25d2e7fcabde4983d53fbe","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-19","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":4300,"enrolmentType":"ESTIMATED","siteCount":709,"recruitingSiteCount":37,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","France","Georgia","Germany","Greece","Hungary","India","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Peru","Philippines","Poland","Portugal","Romania","Serbia","Singapore","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States","Vietnam"]}],"started":"2023-03-31","startedType":"actual","enrolled":4300,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05774951/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"drug":[{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/"},{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/"},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}